Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

537 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.
Pérez R, Jiménez M, Crespo J, Diago M, Enríquez J, Vaquero P, Solá R, Olcoz JL, Romero M, Salmerón J, Blanco MI, Oña M, Melón S, Rodrigo L; Grupo Inter-Hospitalario Español. Pérez R, et al. Among authors: salmeron j. J Viral Hepat. 2003 Nov;10(6):437-45. doi: 10.1046/j.1365-2893.2003.00461.x. J Viral Hepat. 2003. PMID: 14633177 Clinical Trial.
Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
Salmerón J, Diago M, Andrade R, Pérez R, Solá R, Romero M, de la Mata M, Granados R, Ruiz-Extremera A, Muñoz de Rueda P. Salmerón J, et al. J Viral Hepat. 2007 Feb;14(2):89-95. doi: 10.1111/j.1365-2893.2006.00771.x. J Viral Hepat. 2007. PMID: 17244248 Clinical Trial.
Treatment of chronic he1patitis C genotype 1 with peginterferon-alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate.
Diago M, Olveira A, Solá R, Romero-Gómez M, Moreno-Otero R, Pérez R, Salmerón J, Enríquez J, Planas R, Gavilán JC, Del Olmo J, Uribarrena R, Sillero C, Benítez A, Sánchez-Galdón S, Dalmau B, Eraña L, Montoro M, Portu J, Garijo JM, Barniol R, Domínguez A, Rota R, Olcoz JL, Antón M, Pamplona X, Casanovas T, Jiménez E, Huarte M, Díaz F, Sánchez-Ruano J, Orive M, Muñoz-Sánchez M, Roset M. Diago M, et al. Among authors: salmeron j. Aliment Pharmacol Ther. 2007 Apr 15;25(8):899-906. doi: 10.1111/j.1365-2036.2007.03270.x. Aliment Pharmacol Ther. 2007. PMID: 17402993 Free article. Clinical Trial.
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin.
Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, Solà R, García-Samaniego J, Herrerías JM, De la Mata M, Moreno-Otero R, Nuñez O, Olveira A, Durán S, Planas R; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Romero-Gómez M, et al. Among authors: salmeron j. Hepatology. 2009 Dec;50(6):1702-8. doi: 10.1002/hep.23206. Hepatology. 2009. PMID: 19845037 Clinical Trial.
Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C.
Lopez-Rodriguez R, Trapero-Marugan M, Borque MJ, Roman M, Hernandez-Bartolome A, Rodriguez-Muñoz Y, Martin-Vilchez S, Abad-Santos F, Muñoz de Rueda P, Vidal-Castiñeira JR, Rodrigo L, Salmeron J, Moreno-Otero R, Sanz-Cameno P. Lopez-Rodriguez R, et al. Among authors: salmeron j. Clin Pharmacol Ther. 2011 Nov;90(5):712-21. doi: 10.1038/clpt.2011.189. Epub 2011 Oct 12. Clin Pharmacol Ther. 2011. PMID: 21993426
Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP).
Carreño V, Marcellin P, Hadziyannis S, Salmerón J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jiménez FJ, Quiroga JA. Carreño V, et al. Among authors: salmeron j. Hepatology. 1999 Jul;30(1):277-82. doi: 10.1002/hep.510300117. Hepatology. 1999. PMID: 10385667 Clinical Trial.
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
Fernández-Rodríguez CM, Morillas RM, Masnou H, Navarro JM, Bárcena R, González JM, Martín-Martín L, Poyato A, Miquel-Planas M, Jorquera F, Casanovas T, Salmerón J, Calleja JL, Solà R, Alonso S, Planas R, Romero-Gomez M. Fernández-Rodríguez CM, et al. Among authors: salmeron j. Gastroenterol Hepatol. 2014 Jan;37(1):1-8. doi: 10.1016/j.gastrohep.2013.10.005. Epub 2013 Dec 17. Gastroenterol Hepatol. 2014. PMID: 24360571 Clinical Trial.
537 results